Andrew T Lenis, Karissa Whiting, Vignesh Ravichandran, Jacob E Tallman, Syed M Alam, Carissa E Chu, Manual De Jesus Escano, Emily Bochner, Andrew Katims, Peter A Reisz, Hong Truong, Timothy N Clinton, Leon Telis, Shawn Dason, Victor McPherson, Min Yuen Teo, Samuel Funt, David Aggen, Alvin C Goh, Timothy F Donahue, Eugene K Cha, S Machele Donat, Harry W Herr, Guido Dalbagni, Nikolaus Schultz, Michael F Berger, Dean F Bajorin, Jonathan E Rosenberg, Bernard H Bochner, Irina Ostrovnaya, Hikmat Al-Ahmadie, David B Solit, Gopa Iyer, Eugene J Pietzak
PURPOSE: Patients with residual invasive bladder cancer after neoadjuvant chemotherapy (NAC) and radical cystectomy have a poor prognosis. Data on adjuvant therapy for these patients are conflicting. We sought to evaluate the natural history and genomic landscape of chemotherapy-resistant bladder cancer to inform patient management and clinical trials. METHODS: Data were collected on patients with clinically localized muscle-invasive urothelial bladder cancer treated with NAC and cystectomy at our institution between May 15, 2001, and August 15, 2019, and completed four cycles of gemcitabine and cisplatin NAC, excluding those treated with adjuvant therapies...
April 2024: JCO Precision Oncology